Lab21 hires cfo

Susan Lowther joins Cambridge, UK-based firm

Lab21, a Cambridge, UK-based specialist in personalised medicine, has hired Susan Lowther as chief financial officer.

Lowther has spent more than 20 years in the pharmaceutical, biotech and healthcare industries and has held senior management positions at BioWisdom, RiboTargets, Lonza Biologics, Celltech and Monsanto.

Graham Mullis, Lab21 ceo, said: ‘Susan’s financial and life sciences industry expertise, particularly in the area of acquisitions, will be essential as we continue to develop the company.’

You may also like

Research & Development

Lab21 sells South Carolina laboratory operations

Will continue to focus on diagnostic content opportunities within the US market
Finance

Lab21 acquires Myconostica

Expands growing proprietary diagnostic portfolio
Finance

Owlstone Medical wins up to $49.1m award to develop at-home cancer detection tests

The breath and urine tests are part of the POSEIDON programme, which aims to enable accurate, low-cost, accessible cancer screening for all Americans
Ingredients

Roquette launches KLEPTOSE Crysmeb methyl-beta-cyclodextrin for oral and parenteral formulations

The addition of the novel pharmaceutical excipient boosts the company's already extensive cyclodextrins portfolio
Manufacturing

Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia

Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea
Finance

SeaBeLife raises €2 million to advance dual-target cell death therapies

The funding will help fast-track clinical trials for treatments addressing dry age-related macular degeneration and severe acute hepatitis, supporting the company’s innovative approach to blocking two major regulated cell death pathways
Research & Development

Daiichi Sankyo launches third global research institute in San Diego

The company expands its international research footprint with a new San Diego institute, strengthening collaborations in one of the world’s leading life-science hubs and advancing its global drug discovery strategy
Subscribe now